Synergic carcinostatic effects of ascorbic acid and hyperthermia on Ehrlich ascites tumor cell by Saitoh, Y. et al.
94 Experimental Oncology 37, 94–99, 2015 (June)
SYNERGIC CARCINOSTATIC EFFECTS OF ASCORBIC ACID 
AND HYPERTHERMIA ON EHRLICH ASCITES TUMOR CELL
Y. Saitoh1*, T. Yoshimoto1, S. Kato2, N. Miwa3
1Laboratory of Bioscience & Biotechnology for Cell Function Control, Faculty of Life and Environmental 
Sciences, Prefectural University of Hiroshima, 562 Nanatsuka, Shobara, Hiroshima 727–0023, Japan
2Radioisotope Facilities for Medical Science, Life Science Research Center, Mie University, 
2–174 Edobashi, Tsu, Mie 514–8507, Japan
3Department of Radiological Technology, Faculty of Health Sciences, Butsuryo College of Osaka, 
3–33 Ohtorikita-machi, Sakai, Osaka 593–8324, Japan
Aim: In this study, we evaluated the carcinostatic effects of combined ascorbic acid (AsA) and a capacitive-resistive electric transfer 
(CRet) hyperthermic apparatus-induced hyperthermic treatment on Ehrlich ascites tumor (EAT) cells. Materials and Methods: EAT 
cells were exposed to various AsA (0–10 mM) concentrations for 1 h; they subsequently underwent CRet treatment for 15 min 
at 42 °C. Cell viability was assessed by the WST-8 assay 24 h after the combined treatment. Reactive oxygen species involvement was 
evaluated using catalase and tempol; caspase-3/7 activation was determined by their fluorescent substrates; cell proliferation were 
estimated by time-lapse observation. The effect on the cell cycle was analyzed by flow cytometry. Results: Combined AsA and CRet 
treatment synergistically suppressed cell viability compared with either treatment alone, and these synergistically carcinostatic effects 
were evident even at noncytotoxic concentrations of AsA alone (≤ 2 mM). The carcinostatic effects of combined AsA and CRet treat-
ment were attenuated in a dose-dependent manner by catalase addition, but not by the superoxide anion radical scavenger tempol. 
Time-lapse observation revealed that combined AsA and CRet treatment activated caspase-3/7 at 10–24 h after treatment, accom-
panied by significant cell growth suppression. Cell cycle analysis revealed that the rate of sub-G1-phase (apoptotic) cells was drasti-
cally increased at 12 h and 24 h, and that the G2/M-phase cells gradually increased at 6–24 h after treatment. Conclusion: These 
results indicate that combined AsA and CRet treatment synergistically inhibits EAT cell growth through G2/M arrest and apoptosis 
induction via H2O2 generation at lower AsA concentrations; this carcinostatic effect cannot be exer ted by AsA alone.
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Ascorbic acid (AsA) acts as both an antioxidant and 
a pro-oxidant. Typically, it exhibits pro-oxidant properties 
at high concentrations [1] and in the presence of cata-
lytic metal ions, such as iron and copper ions [2]. High 
doses of AsA (millimolar concentrations) reportedly 
inhibit the proliferation of various cancer cell lines [3], 
and the anticancer effect is exerted via H2O2-mediated, 
pro-oxidant mechanism [3–5]. Recently, the high-dose 
AsA treatment has been known as pharmacological AsA, 
which could be achieved through parenteral administra-
tion, such as intravenous infusion; the effects of pharma-
cological AsA on tumor growth in animals have also been 
confirmed in various cancer models, including xeno-
grafts [5–10]. Furthermore, it was demonstrated that high 
(pharmacologic), but not low (physiologic) AsA concen-
trations killed cancer cells but not normal cells, with cell 
death dependent on extracellular AsA concentrations [3, 
4, 6, 11]. Based on these studies, pharmacologic AsA 
is expected to be a more harmless antitumor approach 
with regard to complementary and alternative medicine. 
In addition to these effects of pharmacologic AsA, it has 
also been reported that it can increase the efficacy of se-
veral chemotherapeutic drugs and radiotherapy [12–14], 
and the usage of some agents appears to decrease with 
simultaneous usage of AsA [15]. Therefore, the appro-
priate combination of high-dose AsA and conventional 
anticancer therapeutic strategies may have the potential 
to improve outcomes compared with the treatment alone.
Capacitive-resistive electric transfer (CRet) sys-
tem applies electric currents at frequencies within 
the 0.4–0.6 MHz range to treatment of inflammation 
and musculoskeletal injuries [16–19]. It has been 
demonstrated that CRet system, which can produce 
electric stimuli and thermal effects simultaneously 
in tissues, can induce synergistically cytostatic and/
or cytotoxic effects in tumor tissues [20, 21]. Thus, 
CRet system has been studied as one of a novel ap-
plication in the field of oncology. However, the effect 
of combined treatment with high-dose AsA and CRet 
treatment has not yet been investigated.
In this study, we investigated the carcinostatic ef-
fects of combined high-dose AsA and CRet treatment 
in Ehrlich ascites tumor (EAT) cells. Our results indicate 
that lower concentration of AsA combined with CRet 
synergistically inhibits the growth of EAT cells through 
G2/M arrest and apoptosis induction via H2O2 generation.
MATERIALS AND METHODS
Cell culture. EAT cells (RCB0142) were obtained 
from the RIKEN BRC through the National Bio-Resource 
Project of the MEXT in Japan. Cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM; Nissui Sei-
yaku, Tokyo) supplemented with 10% heat-inactivated 
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fetal bovine serum (FBS, Biological Industries Ltd., Beit 
Haemek, Israel) and 4 mM L-glutamine at 37 °C in a hu-
midified atmosphere of 95% air and 5% CO2.
Cell viability. Cell viability was assessed 
on the basis of the intracellular enzymatic conversion 
of WST-8 to oran ge formazan, which is indicative of cell 
viability. Briefly, cells were rinsed with phenol red-free 
medium and incubated for 3 h in phenol red-free DMEM 
containing 10% of cell-counting kit-8 reagent (Dojindo 
Laboratories, Kumamoto, Japan) at 37 °C. Absorbance 
at 450 nm was measured using a microplate reader 
(FLUOstar Optima; BMG Labtech, Offenburg, Ger-
many). Cell viability was expressed as the per centage 
of absorbance relative to that of the control cells.
CRet system. CRet system can induce local 
hyperthermia induced in the target tissues through 
the mobile electrodes for transdermal application, and 
the treatment has been reported to be more effective 
and less edema formation than other thermal thera-
pies [16]. Preliminary tests of CRet system on cancer 
patients also showed consistent signs of slowing down 
the growth of the tumor tissues without adverse effects 
in the surrounding healthy tissues [20, 21]. Additonally, 
previous studies have shown that CRet treatment in-
duces cytostatic effects in the human hepatocarcinoma 
HepG2 [16, 17, 19], cytotoxic effects in NB69 human 
neuroblastoma cells [18] and significantly potentiate 
anticancer effect of 6-O-palmitoyl-ascorbate on human 
tongue squamous carcinoma HSC-4 [22].
AsA and CRet treatment. EAT cells were seeded 
and preincubated for 24 h, and subsequently treated with 
medium containing 0.1–10 mM AsA, which was titrated 
with NaOH at pH 6.8–7.4, for 1 h to mimic the clinical 
intravenous infusion of AsA [23]. For CRet treatment, 
we used a CRet signal generator (INDIBA DH-308; INDI-
BA S.A., Barcelona, Spain), which produces the electric 
currents of 0.45 MHz and thermal effects synergistically 
in tissues [22, 24]. Exposure to CRet electric currents 
was achieved using pairs of stainless-steel electrodes 
designed ad hoc for in vitro stimulation (Fig. 1), as previ-
ously described [16–19, 22, 24].
Culture medium
Stainless electrodes
Termometer
CRet system
Fig. 1. Diagram of CRet exposure system for in vitro study. 
The pairs of stainless electrodes were inserted in a well and con-
ducted to Cret system (apparatus), and temperature of the cul-
ture medium was monitorned in the well
The electrodes were inserted into each well or dish 
and connected in series to a CRet signal gene rator. 
The signal parameters of CRet system were monitored 
throughout exposure. Temperature of the culture me-
dium reached to 42 °C for approximately 2 min and kept 
for the established period under constant observation 
with thermometer. After AsA treatment for 1 h, cells 
underwent CRet treatment for 15 min at 42 °C or sham 
treatment without electric current; subsequently the 
media were exchanged with fresh media. After incuba-
tion for further 24 h at 37 °C, cell viability was determined 
using the WST-8 method.
Caspase-3/7 activity assay. Caspase-3/7 activa-
tion in individual cells was detected using  CellEvent™ 
caspase-3/7 Green (Life Technologies, CA, USA). 
Cells were seeded into a glass-bottomed, 35-mm dish 
(Matsunami Glass Ind., Ltd., Osaka, Japan) for 24 h. 
After combined AsA and CRet treatment, CellEvent™ 
caspase-3/7 Green solution was added to the dish that 
was subsequently placed in a BioStation IM (Nikon, To-
kyo) and maintained at 37 °C in a humidified atmosphere 
of 95% air and 5% CO2 for time-lapse imaging. The 
fluorescence generated by activated caspase-3/7 was 
periodically observed with excitation and emission 
wavelengths of 485 and 535 nm, respectively.
Cell cycle analysis. Cells were centrifuged at 500 g for 
5 min at 4 °C; and subsequently washed with phosphate-
buffered saline (−). Next, cells were fixed and stained using 
a Cell Cycle Phase Determination kit (Cayman Chemical, 
MI, USA). The stained cells were analyzed by flow cytom-
etry (Guava EasyCyte™; Merck Millipore, MA, USA).
Statistical analysis. Data are expressed as means 
± SD. Statistical comparisons were made using 
the unpaired Student’s t-test or Dunnett’s multiple 
comparisons test. A value of p < 0.05 was considered 
statistically significant.
RESULTS
The suppressive effects of combined AsA and 
CRet treatment on cell viability in EAT cells. To evalu-
ate the effects of combined AsA and CRet treatment 
on cell viability, we exposed EAT cells to various con-
centrations of AsA (0–10 mM) for 1 h, and subsequently 
conducted CRet treatment for 15 min at 42 °C. Cell 
viability was assessed 24 h after treatment. AsA treat-
ment alone suppressed cell viability in a dose-dependent 
manner (≥ 4 mM), whereas CRet treatment alone elicited 
an approximately 42% decrease in cell viability (Fig. 2). 
Conversely, combined AsA and CRet treatment induced 
significant decreases in cell viability at AsA concentra-
tions insufficient to elicit a suppressive effect on cell 
viability by itself (0.1–4 mM). The effect of the combined 
treatment was also superior to that observed on using 
CRet alone with AsA concentrations over 1 mM. Further-
more, the combined treatment was more effective than 
the sum effects of AsA alone and CRet alone. These 
results indicate that combined treatment with AsA and 
CRet exerts a synergistically carcinostatic effect.
The influence of reactive oxygen species (ROS) 
on the suppressive effects of combined AsA and 
CRet treatment. We investigated whether ROS pro-
duction was correlated with the suppressive effect 
on cell viability of combined treatment with AsA and CRet 
using the H2O2 scavenger catalase and the superoxide 
anion radical scavenger tempol [25]. Catalase attenu-
ated the decrease in cell viability in a dose-dependent 
manner (Fig. 3), whereas tempol had no effect. These 
data suggest that H2O2 is responsible for the AsA- and 
CRet-induced anticancer effect in EAT cells, but not 
superoxide anion radicals.
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Fig. 2. The effects of combined AsA and CRet treatment on EAT cells. 
Cells were seeded at a density of 1.5 × 104 cells per well in a 24-well 
plate. After incubation for 24 h, the cells were treated with medium 
containing 0–10 mM of AsA for 1 h to which CRet was applied for 
15 min at 42 °C. A sham operation was conducted in a CRet (−) 
treatment group. Then, the culture media were exchanged with fresh 
media, and cells were incubated for 24 h. Cell viability was assessed 
by the WST-8 assay. Results are expressed as mean ± SD (n = 3–18). 
Significantly different from the CRet (−): *p < 0.01; significantly dif-
ferent from the CRet (+) control: †p < 0.01; significantly different from 
CRet (−) control: ††p < 0.01. Scale bars = 50 μm
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Fig. 3. The outcome of catalase or tempol treatment on the 
anticancer effects induced by combined AsA and CRet treat-
ment. Cells were seeded at a density of 1.5 × 104 cells per 
well in a  24-well plate. After incubation for 24 h, the cells were 
treated with medium containing 2 mM of AsA and catalase (a) 
or tempol (b) for 1 h, to which CRet was applied for 15 min 
at 42 °C. Then, the culture media were exchanged with fresh 
media, and cells were incubated for 24 h. Cell viability was as-
sessed by the WST-8 assay. Results are expressed as mean 
± SD (n = 3–6). Significantly different from the control: *p < 0.01
Combined treatment with AsA and CRet induces 
apoptosis and inhibits cell growth. To elucidate whe-
ther the synergistic anticancer effects of combined AsA 
and CRet treatment are attributable to cell death or growth 
arrest, we observed cellular morphological changes using 
time-lapse apparatus and detected the activity of cas-
pase-3/7 using its substrates. Control cells exhibited time-
dependent cell division during 24 h, but AsA- and CRet-
treated cells barely underwent cell division (Fig. 4, a). After 
incubation for 24 h, the number of cells treated with AsA and 
CRet had decreased slightly relative to the number of cells 
at 0 h (immediately after AsA and CRet treatment), and 
it was significantly suppressed compared with that of the 
control (Fig. 4, b). Furthermore, green-stained activated 
caspase-3/7-positive cells observed 10 h after AsA and 
CRet treatment, gradually increased in a time-dependent 
manner (Fig. 4, a; in the dashed circles). These results sug-
gest that combined treatment with AsA and CRet induces 
both apoptosis and growth inhibition, and that these effects 
play a pivotal role in their anticancer effects.
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Fig. 4. The effects of combined AsA and CRet treatment on cas-
pase-3/7 activation. Cells were seeded at a density of 7.6 × 104 cells 
in a glass-bottomed, 35 mm-dish. After incubation for 24 h, the cells 
were treated with medium containing 2 mM of AsA for 1 h to which 
CRet was applied for 15 min at 42 °C. Then, the culture medium was 
exchanged with fresh medium, and cells were incubated in time-
lapse apparatus. Subsequently, morphologic changes of the cell 
and caspase-3/7 activation-induced green fluorescence were ob-
served by time-lapse system for 24 h (a). Cell number was evaluated 
by counting the cells in three randomly selected fields (b). Results 
are expressed as means ± SD (n = 3). Significantly different from 
the control: *p < 0.05. Scale bars = 50 μm
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The effects of combined AsA and CRet treat-
ment on the cell cycle. As shown in Fig. 5, we analyzed 
the effects of combined AsA and CRet treatment on the 
cell cycle. After treatment, the proportions of sub-G1-, 
G1-, S-, and G2/M-phase cells were similar between the 
control and treated groups until 6 h, but the proportion 
of sub-G1-phase (apoptotic) cells drastically increased 
from 2% at 6 h to 19.7% at 12 h and 6.5% at 24 h (see Fig. 
5). Moreover, the proportion of G1-phase cells was mark-
edly reduced, from 19.4% at 6 h to 10% at 12 h and 12.1% 
at 24 h, whereas the proportion of G2/M-phase cells grad-
ually increased from 41.7% at 6 h to 58% at 24 h following 
AsA and CRet treatment. These results support the theory 
that combined AsA and CRet treatment induces apoptosis 
and growth inhibition through G2/M arrest.
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Fig. 5. The effects of combined AsA and CRet treatment 
on the cell cycle. Cells were seeded at a density of 7.6 × 104 cells 
in a 35-mm dish. After incubation for 24 h, the cells were 
treated with medium containing 2 mM of AsA for 1 h to which 
CRet was applied for 15 min at 42 °C. Then, the culture media 
were exchanged with fresh media, and cells were cultured for 
up to 24 h. At the indicated time, cells were treated with the Cell 
Cycle Phase Determination kit and analyzed by flow cytometry. 
For each sample, 5,000 cells were evaluated
DISCUSSION
In this study, we investigated the combined effect 
of pharmacologic AsA and CRet on the growth of EAT 
cells. Our results indicated that AsA alone decreased cell 
viability in a dose-dependent manner, and significantly 
reduced it at pharmacologic concentrations (≥ 4 mM). 
Furthermore, CRet treatment alone (42 °C, 15 min) 
also significantly decreased cell viability by approxi-
mately 42% compared with the cell viability on incubation 
at 37 °C. We also found that combined AsA and CRet 
treatment significantly reinforced the suppression of cell 
viability compared with that of either treatment alone, 
and that the combination of lower concentrations of AsA 
and CRet elicited a synergistic effect. The enhanced 
suppressive effects of combined AsA and CRet treat-
ment on cell viability were evident even at noncytotoxic 
concentrations of AsA. These results indicate that the 
combined use of AsA and CRet might offer a synergis-
tically enhanced carcinostatic effect at lower AsA con-
centrations than the concentrations used in conventional 
pharmacologic AsA therapy [15, 26].
Thermal sensitization like hyperthermia has been 
demonstrated to induce an increase in ROS, such as su-
peroxide anion radicals and H2O2, apoptosis [27, 28], and 
mitotic catastrophe, through alterations in the proteins 
that support DNA metabolism [29, 30]. Additionally, it was 
also reported that pharmacologic concentrations of AsA 
kill cancer cells but not normal cells via H2O2 [3, 4] and 
ascorbate radical generation [4], and that pharmacologic 
concentrations of AsA slow tumor growth [6, 31]. To inves-
tigate the mechanisms underlying the effect of combined 
treatment with lower concentrations of AsA and CRet, 
we first studied the involvement of superoxide anion 
radicals or H2O2. Catalase abrogated the decrease in cell 
viability elicited by combined AsA and CRet treatment 
in a dose-dependent manner, whereas the membrane-
permeable radical scavenger tempol did not induce a pro-
tective effect against the AsA- and CRet-induced reduc-
tion in cell viability (see Fig. 3). These results suggested 
that H2O2 generation, but not superoxi de anion radicals, 
play a pivotal role in the carcinostatic effects of combined 
treatment with AsA and CRet. It has been established that 
H2O2 is involved in the redox control of several physiologic 
processes, including cell proliferation and apoptosis [32, 
33]. Furthermore, we previously reported that combined 
treatment with AsA and CRet increased ascorbate radical 
formation in HSC-4 cells [22]. Therefore, these results 
suggest that both H2O2 and ascorbate radical genera-
tion are related to the effects of combined treatment with 
AsA and CRet through cell growth suppression because 
of G2/M arrest and apoptosis induction (see Fig. 4 and 5).
It has been demonstrated that CRet system can 
induce synergistically cytostatic and/or cytotoxic ef-
fects in tumor tissues [20, 21]. On the other hand, 
the cytostatic and/or cytotoxic effects of CRet treat-
ment are also confirmed at subthremal doses of CRet 
current in the human hepatocarcinoma HepG2 [16, 17, 
19] and NB69 human neuroblastoma cells [18]. These 
results indicate that the cytostatic and/or cytotoxic ef-
fects could be caused by CRet electric current itself. 
Furthermore, it has been reported that CRet electric 
stimulation at subthermal level induced cytostatic 
and/or cytotoxic effects via induction of cell cycle ar-
rest in phases S and G1 of the cell cycle mediated 
by changes in the expression of cyclins D1, A and 
B1 and of cyclin-dependent kinase inhibitor p27kip1, 
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induction of cytodifferentiation and necrosis [17–19]. 
Thus, our results suggest that the carcinostatic effect 
resulting from combined AsA and CRet treatment may 
be related to an electric stimulus-induced carcinostatic 
and carcinotoxic function.
Pharmacologic AsA concentrations are safely 
achieved in humans by intravenous administration [6, 
11]; high concentrations of AsA selectively kill vari-
ous cancer cells, but not normal cells [3]. Therefore, 
the utilization of pharmacologic AsA is anticipated 
to become a prospective therapeutic anticancer treat-
ment. In fact, high-dose parenteral AsA is currently 
administered to thousands of patients by practitio-
ners of complementary and alternative medicine [15, 
34]. Although intravenously administered high-dose 
AsA is considered to be a relatively innocuous and 
beneficial therapeutic approach for cancer therapy, 
concerns remain about its adverse effects [34–36]. 
Our results indicate that combined AsA and CRet 
treatment can induce a synergistically carcinostatic 
effect at nontoxic AsA concentrations. Therefore, 
our findings might provide a clue to mitigate adverse 
effects of pharmacologic AsA therapy. A previous 
study [3] demonstrated that normal cells were unaf-
fected by 20 mM AsA, whereas five of 10 cancer lines 
that were tested exhibited half-maximal effective 
concentration values of <4 mM following 1 h of AsA 
exposure. In our study, EAT cells were barely affected 
by AsA concentrations of <4 mM; therefore, EAT cells 
appear comparatively AsA-resistant. Nevertheless, 
the combination of AsA and CRet exerted a markedly 
carcinostatic effect at noncytotoxic concentrations 
of AsA. Although additional investigations are neces-
sary for better understanding of these efficacies espe-
cially in human-derived tumor cells and human, these 
results imply the possibility that the combination of AsA 
and CRet treatment can exert carcinostatic effects 
on pharmacologic AsA therapy-resistant tumor cells.
In conclusion, the AsA concentration necessary 
for carcinostatic effects can be reduced by its com-
bination with CRet-induced CRet, and this combined 
treatment with low-concentration AsA (≤ 2 mM) and 
CRet induces more marked and synergistically car-
cinostatic effects than either AsA or CRet treatment 
alone. Moreover, our results demonstrate that these 
carcinostatic effects occurred through the induction 
of apoptosis and the suppression of cell proliferation 
because of G2/M arrest via H2O2 generation. As cancer 
therapies are often combinatorial, AsA in combination 
with CRet is worthy of further examination for the treat-
ment of various types of tumor.
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